{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-056850","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.645816+00:00","generated_at":"2026-06-02T05:00:17.313224+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"MEI Pharma reports Q3 FY2024 cash $56.6M, no revenue; prioritizes voruciclib program","bullets":["Cash, equivalents & investments $56.6M at Mar 31, 2024; no revenue for Q3 vs $5.9M prior year.","R&D expenses $5.2M (down from $15.1M YoY) due to zandelisib wind-down; G&A $4.6M (down from $7.2M).","Voruciclib Phase 1 expansion cohort enrolling; complete responses observed in R/R AML patients.","Board unanimously prioritizes voruciclib, decides against second return of capital under cooperation agreement.","ME-344 formulation development initiated; update expected in first half of calendar 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-056850","json":"https://secwatch.observer/filing/0000950170-24-056850.json","markdown":"https://secwatch.observer/filing/0000950170-24-056850.md","text":"https://secwatch.observer/filing/0000950170-24-056850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/meip-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T05:00:17.313224+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"306c6f9b8ace756c4d0ff4011594c2a92aeb2247","claim":"Lite Strategy, Inc. reported financial results for third quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, MEI Pharma, Inc. (the “Company”) issued a press release announcing its financial results for its third quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a74416eb7daef4f6a585d8e97b7369ea35e67a9a","claim":"Lite Strategy, Inc. reported three and nine months ended March 31, 2024 results: net income As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de.","evidence_excerpt":"As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding debt.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024056850/0000950170-24-056850-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended March 31, 2024"},{"label":"Net income","value":"As of March 31, 2024, MEI had $56.6 million in cash, cash equivalents, and short-term investments with no outstanding de"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}